News

Appili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia ...
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, ...